Syndax Pharmaceuticals Inc
NASDAQ:SNDX

Watchlist Manager
Syndax Pharmaceuticals Inc Logo
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
Watchlist
Price: 13.08 USD 1.79% Market Closed
Market Cap: 1.1B USD
Have any thoughts about
Syndax Pharmaceuticals Inc?
Write Note

Net Margin
Syndax Pharmaceuticals Inc

-1 856.6%
Current
-774%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1 856.6%
=
Net Income
-297.1m
/
Revenue
16m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
1.1B USD
-1 857%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
310.3B USD
9%
US
Amgen Inc
NASDAQ:AMGN
141.6B USD
13%
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD
0%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
134.4B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
35.8B EUR
-14%
Country US
Market Cap 1.1B USD
Net Margin
-1 857%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 310.3B USD
Net Margin
9%
Country US
Market Cap 141.6B USD
Net Margin
13%
Country US
Market Cap 115.3B USD
Net Margin
0%
Country US
Market Cap 102.4B USD
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 134.4B AUD
Net Margin
18%
Country US
Market Cap 77.3B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 35.8B EUR
Net Margin
-14%
No Stocks Found

Syndax Pharmaceuticals Inc
Glance View

Market Cap
1.1B USD
Industry
Biotechnology

Syndax Pharmaceuticals Inc. is carving out a distinctive niche in the biotechnology industry with a focus on developing therapies that modulate critical pathways involved in cancer and severe non-cancer indications. Founded in 2005, Syndax has its sights set on innovative epigenetic and immune-oncology treatments, harnessing the power of scientific breakthroughs to target hard-to-treat conditions. The company's primary approach revolves around inhibiting specific enzymes that alter the expression of genes, thereby reprogramming cancer cells to succumb to therapeutic intervention or effectively arming the immune system to target tumors. This strategic focus is not merely theoretical; it is grounded in a robust pipeline of clinical-stage drug candidates, which they steadily advance through focused research and strategic collaborations. Syndax generates revenue by developing these pioneering treatments and moving them through the rigorous stages of clinical trials towards regulatory approval. The ultimate goal is to bring their breakthrough medications to market, where they can provide significant medical benefits and address unmet needs in the oncology space. Their business model also includes collaborations and partnerships with larger pharmaceutical companies, which often entail milestone payments and royalties. By leveraging these strategic alliances, Syndax not only monetizes its innovations but also gains access to complementary expertise, enhancing its capabilities in developing and commercializing its investigational therapies. Through this two-pronged focus on groundbreaking research and strategic partnerships, Syndax has positioned itself as a dynamic player poised to make significant contributions to the field of medicine.

SNDX Intrinsic Value
14.88 USD
Undervaluation 12%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1 856.6%
=
Net Income
-297.1m
/
Revenue
16m
What is the Net Margin of Syndax Pharmaceuticals Inc?

Based on Syndax Pharmaceuticals Inc's most recent financial statements, the company has Net Margin of -1 856.6%.